Daliresp: Advanced COPD Management for Improved Respiratory Function
| Product dosage: 500 mg | |||
|---|---|---|---|
| Package (num) | Per tab | Price | Buy |
| 30 | $2.28 | $68.33 (0%) | 🛒 Add to cart |
| 60 | $1.84 | $136.66 $110.53 (19%) | 🛒 Add to cart |
| 90 | $1.59 | $204.99 $142.69 (30%) | 🛒 Add to cart |
| 120 | $1.38 | $273.32 $165.80 (39%) | 🛒 Add to cart |
| 180 | $1.23
Best per tab | $409.98 $221.07 (46%) | 🛒 Add to cart |
Daliresp (roflumilast) is a selective phosphodiesterase 4 (PDE4) inhibitor indicated to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations. It represents a significant advancement in the maintenance treatment of chronic obstructive pulmonary disease, targeting underlying inflammation rather than merely alleviating symptoms. By modulating inflammatory pathways, Daliresp offers a novel mechanism of action that complements existing bronchodilator therapies. This oral medication is designed for long-term use as part of a comprehensive COPD management plan under specialist supervision.
Features
- Contains roflumilast as the active pharmaceutical ingredient
- Available in 500 mcg tablet formulation
- Selective phosphodiesterase 4 (PDE4) inhibitor mechanism
- Once-daily oral administration
- Requires prescription and medical supervision
- Manufactured under strict pharmaceutical quality standards
- Packaged with child-resistant safety features
- Includes comprehensive patient information leaflet
Benefits
- Reduces frequency of COPD exacerbations requiring treatment with systemic corticosteroids
- Decreases hospitalizations related to severe respiratory episodes
- Targets underlying inflammation in COPD pathophysiology
- Complements existing bronchodilator therapy without interaction
- Improves quality of life through better disease control
- Provides convenient once-daily dosing regimen
Common use
Daliresp is specifically indicated for the reduction of exacerbations in patients with severe chronic obstructive pulmonary disease (COPD) associated with chronic bronchitis and a history of exacerbations. It is prescribed as maintenance treatment in adults as part of a comprehensive COPD management program. The medication is typically used in conjunction with bronchodilator treatment rather than as monotherapy. Clinical studies have demonstrated efficacy particularly in patients with severe airflow limitation (FEV1 post-bronchodilator less than 50% predicted) and chronic cough with sputum production.
Dosage and direction
The recommended dosage is one 500 mcg tablet taken orally once daily, with or without food. Tablets should be swallowed whole with water and not crushed or chewed. Treatment should be initiated under physician supervision, with regular monitoring of patient response and potential adverse effects. Dose adjustment is not required for elderly patients, but careful monitoring is recommended. For patients with hepatic impairment, Daliresp is contraindicated in moderate to severe liver impairment (Child-Pugh B or C). No dosage adjustment is necessary for renal impairment.
Precautions
Patients should be monitored for weight loss during treatment, as Daliresp has been associated with progressive weight decrease. Regular weight measurement is recommended, with consideration of treatment discontinuation if unexplained or clinically significant weight loss occurs. Psychiatric symptoms including insomnia, anxiety, and depression should be monitored, with particular attention to patients with history of psychiatric disorders. Use with caution in patients with low body mass index (BMI < 18.5 kg/m²). Patients should be advised that Daliresp is not for the treatment of acute bronchospasm and should not be used as rescue medication.
Contraindications
Daliresp is contraindicated in patients with moderate to severe liver impairment (Child-Pugh B or C). It should not be used in patients with a history of hypersensitivity to roflumilast or any component of the formulation. The medication is contraindicated during pregnancy unless the potential benefit justifies the potential risk to the fetus. Breastfeeding is not recommended during treatment. Concomitant administration with strong cytochrome P450 enzyme inducers such as rifampicin, phenobarbital, carbamazepine, or phenytoin is contraindicated due to significantly reduced roflumilast exposure.
Possible side effects
The most common adverse reactions include diarrhea (9.5%), weight decrease (7.5%), nausea (4.7%), headache (4.4%), back pain (3.2%), influenza (2.8%), insomnia (2.4%), dizziness (2.1%), and decreased appetite (2.0%). Psychiatric disorders including anxiety (1.4%) and depression (1.2%) have been reported. Less common but serious side effects may include suicidal ideation and behavior. Gastrointestinal adverse reactions are most frequent during initial treatment and often decrease with continued therapy. Patients should report persistent or severe side effects to their healthcare provider.
Drug interaction
Roflumilast is predominantly metabolized by CYP3A4 and CYP1A2. Concomitant use with strong CYP450 inducers significantly decreases roflumilast exposure and is contraindicated. Co-administration with CYP3A4 inhibitors such as erythromycin, ketoconazole, or fluvoxamine may increase roflumilast exposure. Theophylline administration concurrently with Daliresp is not recommended due to lack of safety data. No clinically significant interactions have been observed with salmeterol, formoterol, budesonide, or digoxin. However, caution is advised when administering with other medications metabolized by CYP pathways.
Missed dose
If a dose is missed, patients should take it as soon as remembered unless it is nearly time for the next scheduled dose. In that case, the missed dose should be skipped and the regular dosing schedule resumed. Patients should not take a double dose to make up for a missed dose. Maintaining regular dosing is important for therapeutic efficacy, but occasional missed doses are not expected to significantly affect overall treatment outcomes. Patients should establish a routine to support adherence to the once-daily regimen.
Overdose
In case of suspected overdose, symptomatic and supportive treatment should be initiated immediately. There is no specific antidote for roflumilast overdose. Reported symptoms in limited overdose experience include gastrointestinal disturbances such as nausea, vomiting, and diarrhea, along with dizziness, palpitations, and lightheadedness. Medical attention should be sought immediately, and treatment should focus on managing symptoms. Gastric lavage may be considered if performed soon after ingestion. Hemodialysis is not expected to enhance elimination due to high protein binding.
Storage
Store at room temperature between 15°C to 30°C (59°F to 86°F) in the original container to protect from moisture. Keep the container tightly closed and out of reach of children and pets. Do not use if the packaging is damaged or shows signs of tampering. Protect from light and excessive humidity. Do not store in bathroom cabinets where moisture levels may fluctuate. Discard any unused medication after the expiration date printed on the packaging. Do not flush medications down the toilet or pour down the drain unless instructed to do so.
Disclaimer
This information is provided for educational purposes only and does not replace professional medical advice. Patients should consult their healthcare provider for personalized medical guidance. The prescribing physician should be aware of the complete medical history of the patient before initiating treatment. This product is available by prescription only and should be used strictly as directed by a qualified healthcare professional. Actual patient experiences may vary, and not all side effects are listed here.
Reviews
Clinical trials have demonstrated that Daliresp significantly reduces the rate of moderate and severe COPD exacerbations by approximately 15-17% compared to placebo. Physicians report particular benefit in patients with frequent exacerbations despite optimized bronchodilator therapy. Many specialists note the value of addressing the inflammatory component of COPD pathophysiology. Some patients report improved quality of life and reduced hospitalization frequency, though gastrointestinal side effects may require management during initial treatment phases. The once-daily oral administration is frequently cited as advantageous for patient compliance compared to inhaled therapies.